Trial reportThe Journal of international medical research2026
Dexmedetomidine versus remifentanil in sedation, analgesia, and vital signs in stereotactic brain biopsy: A randomized, single-blind, active-controlled clinical trial.
Trial report in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveStereotactic frame-based brain biopsy is a minimally invasive neurosurgical technique. Dexmedetomidine, an alpha-2 adrenergic agonist, is known to decrease heart rate, blood pressure, and stress response. Remifentanil is a short-acting opioid receptor agonist. This study compared dexmedetomidine and remifentanil with respect to sedation quality, hemodynamic alterations, analgesia, and recovery profiles during stereotactic brain biopsy.MethodsA total of 140 American Society of Anesthesiology class II patients (72 males, 68 females) were enrolled in a single-blind controlled trial. Patients were randomly divided into the remifentanil group and the dexmedetomidine group. Intraoperative monitoring included blood pressure, oxygen saturation, heart rate, and the Ramsay sedation scale. The visual analog scale score and the total morphine consumption were measured in the postanesthesia care unit.ResultsRamsay sedation scale scores were significantly higher in the remifentanil group (p < 0.001). Heart rate, systolic blood pressure, and diastolic blood pressure were significantly higher in the dexmedetomidine group (p = 0.012, p < 0.001, and p < 0.001, respectively). Visual analog scale scores and total morphine consumption were significantly lower in the dexmedetomidine group (p < 0.001 and p < 0.001, respectively).ConclusionsThe remifentanil group achieved a deeper level of sedation. The dexmedetomidine group had higher mean hemodynamic parameters. The visual analog scale scores and the dose of consumed morphine in the postanesthesia care unit were lower in the dexmedetomidine group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.